^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AGI-101H

    i
    Other names: AGI-101H
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    Vascular disrupting agent
    Related drugs:
    Associations

    News

    Trials
    over3years
    Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization. (PubMed, Cancers (Basel))
    Third, we show that immunization with MA restored natural CD8+ T cell autoimmunity to MA in 85% of the MM patients. The role of natural T cell autoimmunity to tumor-associated MA is discussed based on discrete levels of T cell activation thresholds.
    Journal
    |
    IFNG (Interferon, gamma)
    |
    AGI-101H
    over4years
    Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6. (PubMed, Oncoimmunology)
    In the present study, high levels of BCL6 transcripts negatively correlated with the expression of several exhaustion markers (CTLA4, KLRG1, PTGER2, IKZF2, TIGIT). Therefore, Bcl6 seems to promote a progenitor fate for cancer-experienced T cells from AGI-101H-vaccinated patients by repressing the exhaustion markers.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • IL2 (Interleukin 2)
    |
    AGI-101H